With a market capitalization (market cap) of $2.5B — a measure of how much the company is worth — Hemab Therapeutics Holdings, Inc. Common Stock is the 1955th most valuable company in Healthcare as of August 12, 2026. Shares trade at $53.48, up +3.36% on the day.
of 2,600
price ÷ annual EPS
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission is to enhance life and resilience for patients through innovative therapies. The company's leading pipeline candidate is HMB-001, a bispecific antibody. This asset is currently undergoing Phase 1/2 clinical trials for the preventive management of Glanzmann thrombasthenia and has progressed to Phase 2 for the prophylactic treatment of Factor VII deficiency. Additionally, Hemab is advancing HMB-002, a monovalent antibody, through Phase 1/2 clinical development. This drug is designed for the subcutaneous prophylactic treatment of Von Willebrand disease. Beyond these clinical assets, the company actively pursues numerous preclinical and discovery-stage programs. Established in 2020, Hemab Therapeutics Holdings, Inc. maintains its headquarters in Cambridge, Massachusetts.
Visit websiteAs of August 12, 2026, Hemab Therapeutics Holdings, Inc. Common Stock (COAG) is worth $2.5B — this is its market capitalization, the total value of all its outstanding shares.
Hemab Therapeutics Holdings, Inc. Common Stock’s market cap is $2.5B, which ranks it #1955 among the most valuable companies in the Healthcare sector tracked on MarketCapLens.
Hemab Therapeutics Holdings, Inc. Common Stock (COAG) shares trade at $53.48, up 3.36% on the day, as of August 12, 2026.
Fundamentals are annual. Figures labeled with their fiscal year.
FY 2025